Cetuximab (Targeted Therapy)
Treatment for Larynx cancer
Typical Dosage: 400 mg/m2 loading dose, then 250 mg/m2 weekly
Effectiveness
65%
Safety Score
45%
Clinical Trials
3
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg/m2 loading dose, then 250 mg/m2 weekly
Time to Effect
Weeks
Treatment Duration
Weekly for 7 weeks (with radiation)
Evidence Quality
MODERATEConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$5,000
Side Effect Mgmt:$4,000
Total Annual:$39,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$97,500
Cost per Remission
$195,000
Cetuximab (Targeted Therapy) Outcomes
for Larynx cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+40%
Remission Rate
+20%
Common Side Effects
Acne-like rash
+80%
Hypomagnesemia
+50%
Infusion reactions
+20%
Diarrhea
+25%
Fatigue
+40%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Cetuximab (Targeted Therapy) in Larynx cancer
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
NCT06706401RECRUITINGPHASE3
460 participants
INTERVENTIONAL
Lyon, France +7 more
Started: Feb 20, 2025
Completed Clinical Trials
1 completed trial for Cetuximab (Targeted Therapy) in Larynx cancer
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03082534COMPLETEDPHASE2
78 participants
INTERVENTIONAL
La Jolla, United States +3 more
Started: Mar 28, 2017